HCV genotype 2 as a risk factor for reactivation in patients with B‐cell lymphoma undergoing rituximab combination chemotherapy
- 9 June 2010
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 150 (1) , 116-117
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver diseaseBlood, 2007
- HCV genotype 2 as a risk factor for reactivation of chronic HCV infectionGut, 2005
- Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patientsGut, 2005
- Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare‐upJournal of Medical Virology, 2004
- Effects of corticosteroids on HCV infectionInternational Journal of Immunopharmacology, 1999
- Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic studyJournal of Hepatology, 1996